StressMarq Biosciences Inc. and Cellectricon are pleased to announce a collaboration to develop next-generation reagents and assays for neurodegenerative disease research.

StressMarq offers a unique reagent portfolio of pre-formed fibrils and oligomers for tau, alpha-synuclein, amyloid beta, and other proteins that can be used to study diseases such as Alzheimer’s and Parkinson’s. StressMarq is the market leader in the development and commercialization of a range of unique fibrillar, oligomeric, and monomeric protein preparations for use in neurodegenerative disease research, including proteins such as alpha synuclein, tau, amyloid beta, SOD1 and TTR. StressMarq’s strategic efforts are focused on expanding the breadth and depth of this product offering to assist researchers studying Alzheimer’s, Parkinson’s, and other neurodegenerative diseases.

Cellectricon is a collaborative services provider dedicated to advancing drug discovery and research in the areas of chronic pain and neurodegenerative disease. They have developed a high capacity microfluidics platform to model the hallmark features of neurodegenerative diseases, including cell-to-cell transmission of neurodegenerative disease associated peptides (NDAPs) in neuronal circuits.

The two companies will work together to provide the scientific community with next-generation reagents and assays for neurodegenerative disease research. Ariel Louwrier, President & CEO of StressMarq Biosciences and Sebastian Illes, Director of CNS research at Cellectricon recently presented a webinar about fibrillar and oligomeric constructs of neurodegenerative disease associated peptides and their utility in disease modelling.

Learn more about StressMarq’s cutting-edge products for neurodegenerative disease research  and Cellectricon’s Pain and CNS Discovery Services.